NCT01640405已完成3 期
Phase III, Randomized Clinical Trial to Evaluate FOLFOX + Bevacizumab Versus FOLFOXIRI + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells.
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)1 个研究点 分布在 1 个国家目标入组 350 人开始时间: 2012年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 350
- 试验地点
- 1
- 主要终点
- Progression free survival (PFS)
研究概览
简要总结
The purpose of the study is to evaluate FOLFOX + bevacizumab versus FOLFOXIRI + bevacizumab as first line treatment of patients with metastatic colorectal cancer not previously treated and with three or more circulating tumoral cells.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient's Informed consent in written.
- •Age between 18 and 70 years old.
- •Eastern Cooperative Oncology group performance status (ECOG) 0-
- •Life expectancy of at least 3 months.
- •Histological confirmation of adenocarcinoma of the colon or rectum.
- •To be included in the study patients should present > or equal 3 CTC in peripheral blood.
- •Measurable metastatic stage IV disease with at least 1 measurable metastatic lesion following Response Evaluation Criteria In Solid Tumors (RECIST) criteria v 1.1 (non suitable for radical surgery at the inclusion time).
- •Prior radiotherapy is allowed but must be completed at least 4 weeks before randomization (if applicable).
- •Adequate bone marrow, liver and renal function.
- •Women of childbearing potential must have a negative serum or urine pregnancy test. Postmenopausal women must have been amenorrheic for at least 12 months.Both men and women participating in this study must use adequate contraception.
- •Subject must have the ability, in the opinion of the investigator, to comply with all the study procedures and follow-up examinations.
排除标准
- •Previous chemotherapy for metastatic disease.
- •Prior treatment with Bevacizumab, or Epidermal Growth Factor Reception (EGFR) inhibitors
- •Any anticancer treatment (chemotherapy, hormonal treatment, radiation treatment, surgery , immunotherapy, biologic therapy or tumour embolization) within 4 weeks before randomization.
- •Use of any investigational drug within 4 weeks before start the treatment
- •Clinical or radiographic evidence of brain metastasis.
- •Uncontrolled hypertension (systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg on repeated measurement) despite optimal medical management.
- •Previous history of hypertensive encephalopathy or hypertensive crises.
- •Current or history of peripheral neuropathy > or equal to 1 National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE).
- •Patients classified as fragile according to criteria listed in the protocol.
- •Significant cardiovascular disease (e.g. cerebrovascular accident (CVA), myocardial infarction, within 6 months before randomization). Unstable angina, congestive heart failure New York Heart Association (NYHA) ≥ class II, arrhythmia that requires treatment within 3 months before randomization.
- •Significant vascular disease (e.g. aortic aneurism requiring surgical intervention, pulmonary embolic, peripheral arterial thrombosis) within 6 months before randomization.
- •Previous history of significant haemorrhage /severe, within 1 month before randomization.
- •Major surgery, open surgical biopsy or significant traumatic injury within 4 weeks before randomization.
- •Large bore needle biopsy of a major organ within 14 days before randomization. Placement of central venous access port > or equal to 7 days before randomization is permitted
- •Evidence or history of bleeding diathesis or coagulopathy.
- •International Normalized Ratio (INR) > 1.5 within 14 days prior to starting study treatment. EXEMPTION: patients on full anticoagulation must have an in-range INR [usually between 2-3]. Any anticoagulation therapy must be at stable dosing prior to enrollment.
- •History of previous abdominal fistula or gastrointestinal perforation within 6 months before randomization.
- •Serious non-healing wound, ulcer or bone fracture.
- •Acute or sub-acute of intestinal occlusion or history of intestinal inflammatory disease.
- •History of uncontrolled convulsive crises.
- •History of pulmonary fibrosis, acute lung disease or interstitial pneumonia.
- •Chronic, actual o recent use (10 days prior first drug administration) of acetylsalicylic acic (aspirin) > 325 mg/day or clopidogrel (75mg/day) or other treatments that can cause gastrointestinal ulcer (low-dose aspirin is permitted < or equal to 325 mg/day).
- •Urinary protein excretion > or equal to 2+ (dipstick). If > or equal 2 g proteinuria is detected with dipstick, a 24-hour period urine test will be performed and the result should be < or equal to 1 g/24 hours to permit the inclusion of the patient in the clinical trial.
- •Known human immunodeficiency virus infection or chronic hepatitis B or C infection or other uncontrolled, severe concurrent infection .
- •Current infection > or equal to Grade 2 (NCI-CTCAE).
- •Any previous or concurrent cancer different to colorectal carcinoma within 5 years before to start the treatment. Subjects with successfully treated, non-invasive cancers, including cervical cancer in situ, basal cell carcinoma will be allowed to participate in the clinical trial. Or those cancer treated with curative intention without disease evidence in the last 5 years at least.
- •Known or suspected allergy or hypersensitivity to any component of Bevacizumab, oxaliplatin, irinotecan, or 5-FU/LV.
- •Any medical, psychological, or social condition that may interfere with the subject's participation in the study or evaluation of the study results.
- •Any psychological, familial or geographic situation that interferes in the adequate follow.up and adherence to the study protocol.
- •Women who are pregnant or breast-feeding.
研究组 & 干预措施
Control
Active Comparator
modified FOLFOX6 + bevacizumab
干预措施: modified FOLFOX6 + bevacizumab (Drug)
Experimental
Experimental
FOLFOXIRI+bevacizumab
干预措施: FOLFOXIRI + Bevacizumab (Drug)
结局指标
主要结局
Progression free survival (PFS)
时间窗: 5 years
次要结局
- Overall survival (OS)(5 years)
- Response rate (RR)(5 years)
- Circulating Tumour Cells (CTC) count basal and correlate to PFS, OS, RR(5 years)
- Correlation of RAS, BRAF and PI3K mutations and clinical anti-tumour activity outcome ( PFS, OS, RR)(5 years)
- Radical Resection (R0) surgery rate(5 years)
- Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)(5 years)
- Adverse events(5 years)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
3 期
Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal CancerColorectal CancerNCT03635021Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)419
进行中（未招募）
1 期
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal CancerMetastatic Colon AdenocarcinomaMetastatic Colorectal AdenocarcinomaMetastatic Microsatellite Stable Colorectal CarcinomaMetastatic Rectal AdenocarcinomaStage IV Colon Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IV Rectal Cancer AJCC v8NCT05627635City of Hope Medical Center20
已完成
2 期
Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic CancerMetastatic Pancreatic CancerNCT00786006Asan Medical Center61
Unknown
2 期
A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus BevacizumabColorectal CancerNCT02515734Japan Clinical Cancer Research Organization360
已完成
不适用
First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal CancerMetastatic Colorectal CancerNCT01437618Azienda Ospedaliero, Universitaria Pisana15